NCT00019461已完成2 期
A Phase II Trial of Orally Administered CAI for Patients With Persistent or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients with refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.
详细描述
OBJECTIVES:
- Determine the clinical outcome in patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer treated with carboxyamidotriazole.
OUTLINE: Patients receive oral carboxyamidotriazole daily beginning on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 19-40 patients will be accrued for this study within 2 years.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Irinotecan in Treating Patients With Advanced Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00004051Memorial Sloan Kettering Cancer Center40
已完成
1 期
Combination Chemotherapy in Treating Patients With Advanced CancerUnspecified Adult Solid Tumor, Protocol SpecificLymphomaNCT00003956Memorial Sloan Kettering Cancer Center25
已完成
2 期
Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With OligodendrogliomaBrain and Central Nervous System TumorsNCT00003101Memorial Sloan Kettering Cancer Center60
Unknown
2 期
ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung CancerLung CancerNCT00021008Jonsson Comprehensive Cancer Center
已完成
2 期
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract CancerTransitional Cell Cancer of the Renal Pelvis and UreterBladder CancerNCT00028860Tulane University Health Sciences Center